NASDAQ:RGLSRegulus Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Regulus Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.69 -0.01 (-2.09 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.66Now: $0.69▼$0.7150-Day Range$0.68MA: $0.81▼$0.9652-Week Range$0.43Now: $0.69▼$1.74Volume1.64 million shsAverage Volume4.77 million shsMarket Capitalization$14.47 millionP/E RatioN/ADividend YieldN/ABeta2.04 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.25, Regulus Therapeutics has a potential upside of 81.7% from its current price of $0.69.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesRegulus Therapeutics has received 452 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRegulus Therapeutics has received 321 “underperform” votes. (Add your “underperform” vote.)Community SentimentRegulus Therapeutics has received 58.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote “Outperform” if you believe RGLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,361.00 in company stock.Percentage Held by InsidersOnly 18.24% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions40.94% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.69) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGLS Previous Symbol CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone858-202-6300Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.70Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.83 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book0.72Profitability EPS (Most Recent Fiscal Year)($1.08) Net Income$-18,590,000.00 Net Margins-351.32% Return on Equity-215.33% Return on Assets-68.51%Miscellaneous Employees24 Outstanding Shares21,040,000Market Cap$14.47 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable $0.69 -0.01 (-2.09 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RGLS News and Ratings via Email Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions How has Regulus Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Regulus Therapeutics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGLS shares have increased by 14.7% and is now trading at $0.6879. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Regulus Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Regulus Therapeutics. When is Regulus Therapeutics' next earnings date? Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Regulus Therapeutics. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc (NASDAQ:RGLS) announced its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.13. The biopharmaceutical company had revenue of $6 million for the quarter, compared to analyst estimates of $10 million. Regulus Therapeutics had a negative net margin of 351.32% and a negative return on equity of 215.33%. View Regulus Therapeutics' earnings history. What price target have analysts set for RGLS? 3 brokerages have issued 12 month target prices for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $1.50. On average, they anticipate Regulus Therapeutics' share price to reach $1.25 in the next year. This suggests a possible upside of 81.7% from the stock's current price. View analysts' price targets for Regulus Therapeutics. What are Wall Street analysts saying about Regulus Therapeutics stock? Here are some recent quotes from research analysts about Regulus Therapeutics stock: 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (5/19/2020) 2. HC Wainwright analysts commented, "We have assessed Regulus Therapeutics using a discounted cash flow (DCF)-based approach, which ascribes value solely to the RGLS4326 program and the development-related milestone payments slated to be paid by Sanofi contingent upon continued progress with RG-012. Our assumptions include a 15% probability of regulatory approval for 20% probability of continued clinical advancement for RG-012. We also utilize a 15% discount rate, 0.5% terminal growth rate and 30% effective tax rate." (9/6/2019) Has Regulus Therapeutics been receiving favorable news coverage? News articles about RGLS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Regulus Therapeutics earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about Regulus Therapeutics. Who are some of Regulus Therapeutics' key competitors? Some companies that are related to Regulus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro BioTech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Achillion Pharmaceuticals (ACHN), Array Biopharma (ARRY) and Aurinia Pharmaceuticals (AUPH). Who are Regulus Therapeutics' key executives? Regulus Therapeutics' management team includes the following people: Mr. Joseph P. Hagan, Pres, CEO & Director (Age 50)Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)Mr. Christopher Ray Aker J.D., VP of Legal Affairs & Corp. Sec.Mr. Turner Jenkins, Director & Head of Corp. Devel. What is Regulus Therapeutics' stock symbol? Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS." How do I buy shares of Regulus Therapeutics? Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Regulus Therapeutics' stock price today? One share of RGLS stock can currently be purchased for approximately $0.69. How big of a company is Regulus Therapeutics? Regulus Therapeutics has a market capitalization of $14.47 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-18,590,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Regulus Therapeutics employs 24 workers across the globe. What is Regulus Therapeutics' official website? The official website for Regulus Therapeutics is www.regulusrx.com. How can I contact Regulus Therapeutics? Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
